After lengthy discussions, on Tuesday, drugmaker AbbVie announced that it is acquiring Allergan–the maker of the anti-aging treatment we women all do, but don’t talk about–for $63 billion. It’s one of the biggest mergers in the healthcare sector this year. The healthcare experts we spoke to say it’s a win-win for both parties: it will deliver a new source of growth for AbbVie (It’s been too heavily reliant on revenue from Humira, the arthritis drug it produces), and will provide a second wind for Allergan, which has struggled with all sorts of issues – from drug trial setbacks, disappointments with capital deployment, to strategic missteps.

 Get NoPo Delivered Daily

We hate SPAM as much as you do! Rest assured, your information stays private as per our privacy policy.

Connect With Us